PINE BROOK, N.J., Dec. 13 /PRNewswire/ -- Elusys Therapeutics Inc., a
developer of targeted anti-infective therapeutics, today announced that
ETI-211, the Company's Heteropolymer (HP) Antibody drug candidate targeting
methicillin resistant Staphylococcus aureus (MRSA) infections, will be the
subject of two presentations at the 45th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC).
Nehal Mohamed, Ph.D., of Elusys Therapeutics will make a late-breaking
presentation (#LB-8) entitled, "A Heteropolymer Directed Against
Staphylococcal Protein A Prevents Spread Of Blood-Borne S. aureus To Organs,"
on Saturday, December 17, 2005 from 10:00-11:30 AM.
Steven M. Jones, Ph.D., of Elusys Therapeutics, will make a second
presentation (#G-921) entitled, "A Novel Vaccination Approach Using an
Antibody Conjugate Targeting S. aureus," on Saturday, December 17, 2005 from
11:30-1:00 PM.
The ICAAC conference, which will be held December 16-19, 2005 in
Washington, DC, attracts more than 12,000 physicians, researches and
healthcare professionals from around the world to foster solutions to the many
problems relating to infectious diseases. For more information about ICAAC
please visit http://www.icaac.org.
About HP Antibody Technology
Elusys' Heteropolymer Antibody (HP) technology is a unique approach to the
treatment of infectious disease by enhancing the effectiveness of the body's
natural defense mechanisms to remove and destroy pathogens. An HP antibody
drug consists of a monoclonal antibody specific to a red blood cell receptor
(CR1) that is chemically linked to a second antibody or receptor that binds a
particular pathogen.
After administration, an HP Antibody drug rapidly binds target pathogens
to red blood cells and facilitates their clearance and destruction via liver
macrophages. An animation of this technology is provided via the following
link: http://www.elusys.com/technology_hp_animation.php
About Elusys
Elusys is a privately-held biopharmaceutical company focused on the
development of targeted anti-infective therapeutics using proprietary
Heteropolymer (HP) Antibodies for the treatment of infectious diseases. The
Company's lead product, Anthim(TM), a therapeutic for anthrax, is currently in
advanced development and is a lead candidate for purchase by the US Government
under Project Bioshield. Current investors include Essex Woodlands Health
Ventures LLC, Invesco Private Capital, Crescendo Ventures, EagleAdvisors, and
the Legg Mason Emerald Fund. For more information on Elusys please visit
http://www.elusys.com.
SOURCE Elusys Therapeutics Inc.
 back to top
Related links:
http://www.elusys.com
http://www.icaac.org
http://www.elusys.com/technology_hp_animation.php
CONTACT:
Bryan Murphy of LaVoie Group for Elusys
Therapeutics Inc., +1-781-596-0200 ext-105,
bmurphy@lavoiegroup.com
NOTE TO EDITORS: Elusys spokespeople available at ICAAC
|
